More Apellis Pharmaceuticals, Inc. news Apellis Pharmaceuticals, Inc.NASDAQ: APLS Pivotal VALIANT Results Presented at Kidney Week Highlight Strength of Pegcetacoplan Treatment Effect in Patients with C3G / Primary IC-MPGN Oct 26, 2024 · Issued by Apellis Pharmaceuticals, Inc. As issuedPlain English Watch Apellis Pharmaceuticals explain it↗Apellis Pharmaceuticals, Inc. (APLS) Q4 2025 Earnings Call · Replay · Feb 24Statistically significant 68% (p
